Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822004 | 0.90 | CYP1A2 (0.44) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL31462534 | 0.87 | GAA (0.41) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL5655019 | 0.87 | HDAC1 (0.44) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL21423523 | 0.85 | MEN1 (0.35) | HDAC6HDAC1HDAC2MEN1KMT2A | |
| SCHEMBL9354292 | 0.85 | GAA (0.54) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL22303932 | 0.84 | NFKB1 (0.43) | CA12CA1CA2CA9HDAC6 | |
| SCHEMBL6018881 | 0.82 | ALDH1A1 (0.39) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL6018889 | 0.82 | ALDH1A1 (0.39) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL5884651 | 0.82 | MEN1 (0.52) | CA12CA1CA2HDAC6HDAC1 | |
| SCHEMBL28315095 | 0.82 | HDAC6 (0.37) | CA12CA1CA2HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122662-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-3478683-B1 | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-109641896-A | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | 诺维拉治疗公司 | 2019-04-16 | — | — | CN | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| CN-101513402-B | Antiviral agent | SHIONOGI & CO | 2012-03-21 | — | — | CN | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| CN-101513402-A | Antiviral agent | SHIONOGI & CO (JP) | 2009-08-26 | — | — | CN | disclosed |
| CN-100491349-C | Antiviral agent | SHIONOGI & CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| CN-1675209-A | Dihydropyrazolopyridine compounds | MITSUBISHI PHARMA CORP (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1537106-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2005-06-08 | — | — | EP | disclosed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | SMN1; SMN2 3254/4885CA12 932/4885CA1 423/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | SMN1; SMN2 3746/4885CA12 4630/4885CA1 4422/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | SMN1; SMN2 1242/4885CA12 2846/4885CA1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.